259 related articles for article (PubMed ID: 7536207)
1. Characterization of the paradoxical growth hormone inhibitory effect of galanin in acromegaly.
Giustina A; Bresciani E; Bussi AR; Bollati A; Bonfanti C; Bugari G; Chiesa L; Giustina G
J Clin Endocrinol Metab; 1995 Apr; 80(4):1333-40. PubMed ID: 7536207
[TBL] [Abstract][Full Text] [Related]
2. Galanin decreases circulating growth hormone levels in acromegaly.
Giustina A; Bodini C; Doga M; Schettino M; Pizzocolo G; Giustina G
J Clin Endocrinol Metab; 1992 Jun; 74(6):1296-300. PubMed ID: 1375598
[TBL] [Abstract][Full Text] [Related]
3. Effects of metoclopramide on the paradoxical growth hormone response to galanin in acromegaly.
Giustina A; Doga M; Bodini C; Bossoni S; Bresciani E; Bussi AR
Endocr Res; 1993 Dec; 19(4):303-15. PubMed ID: 7508379
[TBL] [Abstract][Full Text] [Related]
4. Effect of long-term treatment with bromocriptine on the growth hormone response to galanin in patients with acromegaly.
Giustina A; Doga M; Bussi AR; Licini M; Schettino M
Acta Endocrinol (Copenh); 1993 Feb; 128(2):131-5. PubMed ID: 7680832
[TBL] [Abstract][Full Text] [Related]
5. Effect of galanin on the growth hormone response to growth hormone-releasing hormone in acromegaly.
Giustina A; Schettino M; Bodini C; Doga M; Licini M; Giustina G
Metabolism; 1992 Dec; 41(12):1291-4. PubMed ID: 1281259
[TBL] [Abstract][Full Text] [Related]
6. Biochemical evaluation of patients with active acromegaly and type 2 diabetes mellitus: efficacy and safety of the galanin test.
Mazziotti G; Bonadonna S; Doga M; Patelli I; Gazzaruso C; Solerte SB; De Menis E; Giustina A
Neuroendocrinology; 2008; 88(4):299-304. PubMed ID: 18617732
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of selective transsphenoidal adenomectomy by endocrinological testing and somatomedin-C measurement in acromegaly.
Losa M; Oeckler R; Schopohl J; Müller OA; Alba-Lopez J; von Werder K
J Neurosurg; 1989 Apr; 70(4):561-7. PubMed ID: 2647918
[TBL] [Abstract][Full Text] [Related]
8. [Reevaluation of the I-dopa test in acromegaly: anatomo-clinical and prognostic correlations].
De Marinis L; Mancini A; Zuppi P; Fiumara C; Iacona T; Conte G; Fabrizi ML; Valle D; Anile C; Maira G
Minerva Chir; 1993 Nov; 48(21-22):1337-40. PubMed ID: 8152567
[TBL] [Abstract][Full Text] [Related]
9. Studies on the response of growth hormone (GH) secretion to GH-releasing hormone, thyrotropin-releasing hormone, gonadotropin-releasing hormone, and somatostatin in acromegaly.
Shibasaki T; Hotta M; Masuda A; Imaki T; Obara N; Hizuka N; Takano K; Wakabayashi I; Demura H; Ling N
J Clin Endocrinol Metab; 1986 Jul; 63(1):167-73. PubMed ID: 2872226
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone (GH) and prolactin responses to repetitive administration of GH-releasing hormone in acromegaly.
Losa M; Schopohl J; König A; Müller OA; von Werder K
J Clin Endocrinol Metab; 1986 Aug; 63(2):475-80. PubMed ID: 3088026
[TBL] [Abstract][Full Text] [Related]
11. Lack of desensitization of adenomatous somatotrophs to growth-hormone releasing hormone in acromegaly.
Spada A; Elahi FR; Arosio M; Sartorio A; Guglielmino L; Vallar L; Faglia G
J Clin Endocrinol Metab; 1987 Mar; 64(3):585-91. PubMed ID: 3102543
[TBL] [Abstract][Full Text] [Related]
12. Growth hormone secretory response to intravenous galanin infusion in acromegalic patients.
Cuerda C; Lucas T; Silvestre RA; Bretón I; García P; Marco J; Barceló B
Exp Clin Endocrinol Diabetes; 1998; 106(1):68-73. PubMed ID: 9516063
[TBL] [Abstract][Full Text] [Related]
13. The GH-releasing hormone (GHRH) test in acromegaly before and after adenomectomy.
Giusti M; Lomeo A; Monachesi M; Mazzocchi G; Attanasio R; Sessarego P; Mignone D; Del Monte P; Giordano G
J Endocrinol Invest; 1987 Apr; 10(2):143-51. PubMed ID: 3108356
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone-releasing hormone infusion in patients with active acromegaly.
Losa M; Chiodini PG; Liuzzi A; König A; Müller OA; Schopohl J; von Werder K
J Clin Endocrinol Metab; 1986 Jul; 63(1):88-93. PubMed ID: 3086362
[TBL] [Abstract][Full Text] [Related]
15. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
16. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the sensitivity of growth hormone secretion to somatostatin in vivo and in vitro in acromegaly.
Kelijman M; Williams TC; Downs TR; Frohman LA
J Clin Endocrinol Metab; 1988 Nov; 67(5):958-63. PubMed ID: 2903171
[TBL] [Abstract][Full Text] [Related]
18. Effects of metoclopramide on the growth hormone response to galanin in normal man.
Giustina A; Bussi AR; Doga M; Licini M; Schettino M; Wehrenberg WB
Horm Metab Res; 1993 Sep; 25(9):489-92. PubMed ID: 7693566
[TBL] [Abstract][Full Text] [Related]
19. Effect of thyrotropin-releasing hormone and bromoergocriptine on growth hormone and prolactin secretion in perfused pituitary adenoma tissues of acromegaly.
Ishibashi M; Yamaji T
J Clin Endocrinol Metab; 1978 Dec; 47(6):1251-6. PubMed ID: 122426
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
